• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Moolec Science SA

    12/16/25 5:28:19 PM ET
    $MLEC
    Blank Checks
    Finance
    Get the next $MLEC alert in real time by email
    6-K 1 ea0269987-6k_moolec.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

     

    Pursuant to Rule 13a-16 or 15d-16 of the

    Securities Exchange Act of 1934

     

    For the month of December 2025

     

    Commission File Number: 001-41586

     

     

     

    MOOLEC SCIENCE SA

    (Exact name of Registrant as Specified in Its Charter)

     

    89 Nexus Way, Camana Bay

    Grand Cayman KY1-9009

    Cayman Islands

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Form 6-K is incorporated by reference into the Company’s registration statement on Form S-8 (Registration No. 333-282263).

     

    Moolec Science SA holds an Extraordinary General Meeting of Shareholders

      

    Moolec Science SA (NASDAQ: MLEC), a public limited liability company incorporated under the laws of the Cayman Islands, with its registered office at 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands (“Moolec,” the “Company,” “we,” “us,” or “our”), held a virtual extraordinary general meeting of shareholders (the “EGM”), on December 16, 2025, at 9:00 am (Eastern Time).

     

    A total of 4,804,341 ordinary shares out of 10,891,761 ordinary shares entitled to vote (representing 44.110%) were represented at the meeting. As the statutory quorum was not met, the quorum was constituted by the shareholders holding approximately 44.110% of the Company’s total outstanding ordinary shares who were present, either in person or by proxy, in accordance with applicable law and the Company’s articles of association.

     

    At or prior to the Extraordinary General Meeting, the Company’s shareholders voted on the two proposals set forth below. As the adjournment proposal was not required, it was not submitted to a vote. Proposal 1 was approved by more than a simple majority of the votes cast, and Proposal 2 was approved by more than a two-thirds majority of the votes cast, in each case at or prior to the EGM and in accordance with applicable law and the Company’s articles of association.

     

    The EGM considered and voted on the following agenda points:

     

    Resolution 1: Approval of the Share Consolidation

     

    IT IS RESOLVED, AS AN ORDINARY RESOLUTION THAT, pursuant to article 8 of the Company’s current memorandum and articles of association (the “Articles”), the consolidation of every issued and unissued ordinary share, par value US$0.10 per share, of the Company (the “Ordinary Shares”), at a ratio within a range of not less than 1-for-10 and not greater than 1-for-25 (the “Share Consolidation”), with the exact ratio to be determined by further action at the discretion of the Board to be effective on a date between December 17, 2025 and May 14, 2026 as may be determined by the Board and announced by the Company (the “Effective Date”), so that all shareholders holding every 10 to 25 Ordinary Shares (the “Pre-Consolidation Ordinary Shares”) will hold 1 Ordinary Share of par value US$1.00 to US$2.50 each (the “Post-Consolidation Ordinary Shares”), with such Post-Consolidation Ordinary Shares having the same rights and being subject to the same restrictions as the Pre-Consolidation Ordinary Shares as set out in the amended and restated memorandum and articles of association in effect at the time of Effective Date, and with any fractional shares created as a result of the Share Consolidation to be rounded up to the nearest whole, share be approved.

     

    1

     

     

    Resolution 2: Approval of the A&R M&A

     

    IT IS RESOLVED, AS A SPECIAL RESOLUTION THAT, immediately following the Effective Date, the Company shall adopt the amended and restated memorandum and articles of association in the form annexed to the proxy statement (the “A&R M&A”) in substitution for, and to the exclusion of, the Company’s existing Articles, to reflect the Share Consolidation and the terms of the Post-Consolidation Ordinary Shares.

     

    Forward-looking Statements

     

    This report contains “forward-looking statements.” Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company’s performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this report will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including those risk factors included under the header “Risk Factors” in Moolec’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (“SEC”), as well as Moolec’s other filings with the SEC. Should one or more of such risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

    SIGNATURE

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Moolec Science SA
      (registrant)
       
    Date: December 16, 2025 By: /s/ Alejandro Antalich
      Name: Alejandro Antalich
      Title: Chief Executive Officer

     

     

    3

     

    Get the next $MLEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLEC

    DatePrice TargetRatingAnalyst
    9/27/2023$5.00Buy
    ROTH MKM
    More analyst ratings

    $MLEC
    SEC Filings

    View All

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    12/16/25 5:28:19 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    12/12/25 4:43:04 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form 6-K filed by Moolec Science SA

    6-K - Moolec Science SA (0001937737) (Filer)

    11/28/25 2:14:57 PM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

    LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here. "With USDA approval for our GE pe

    10/16/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science Presents Fiscal Year 2024 Annual Business Update

    LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge. Also, Moolec made significant advancements in both upstream and downstream processes.Piggy Sooy™: Field trials in three different US locations continue on sch

    10/2/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

    LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.The Conference Call will be accompanied by a pr

    9/25/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Moolec Science with a new price target

    ROTH MKM initiated coverage of Moolec Science with a rating of Buy and set a new price target of $5.00

    9/27/23 7:44:02 AM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    Financials

    Live finance-specific insights

    View All

    Moolec Science Presents Fiscal Year 2024 Annual Business Update

    LUXEMBOURG / ACCESSWIRE / October 2, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for the fourth quarter of Fiscal Year 2024 ended June 30, 2024. Moolec Science Logo The main highlights of Moolec's fourth quarter are as follows:GLASO™: The Company announced an offtake agreement with a major global CPG food and pet food company and an R&D collaboration agreement with Bunge. Also, Moolec made significant advancements in both upstream and downstream processes.Piggy Sooy™: Field trials in three different US locations continue on sch

    10/2/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

    LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens.Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Wednesday, October 2, 2024 at 08:30am ET.The Conference Call will be accompanied by a pr

    9/25/24 6:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    Moolec Science to Host Third Quarter Fiscal Year 2024 Business Update Conference Call

    LUXEMBOURG / ACCESSWIRE / May 23, 2024 / Moolec Science SA (NASDAQ:MLEC)("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Third Quarter Fiscal Year 2024 on Thursday, May 30, 2024, before the market opens. Moolec Logo Moolec Science Logo Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra, will host a live Conference Call, followed by a question-and-answer session, on Thursday, May 30, 2024, at 08:30 a.m. ET.The Conference Call will be accompanied by a presentation

    5/23/24 7:00:00 AM ET
    $MLEC
    Blank Checks
    Finance

    $MLEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Moolec Science SA

    SC 13D - Moolec Science SA (0001937737) (Subject)

    4/17/24 5:14:28 PM ET
    $MLEC
    Blank Checks
    Finance

    SEC Form SC 13D/A filed by Moolec Science SA (Amendment)

    SC 13D/A - Moolec Science SA (0001937737) (Subject)

    4/10/24 9:39:03 PM ET
    $MLEC
    Blank Checks
    Finance